Information  X 
Enter a valid email address

Nuformix PLC (NFX)

  Print      Mail a friend

Monday 29 March, 2021

Nuformix PLC

Result of General Meeting and Total Voting Rights

RNS Number : 8160T
Nuformix PLC
29 March 2021
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA,

CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

 

Nuformix plc

("Nuformix" or the "Company")

 

Result of General Meeting

 and

 Total Voting Rights

 

London, UK - 29 March 2021:   Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, further to the announcement made in connection with the Placing on 10 March 2021, at the General

Meeting held earlier today all Resolutions put to Shareholders were duly passed.

 

Accordingly, the Company has raised, in aggregate, gross proceeds of £1.565 million.

 

Applications have been made to the FCA for the Placing Shares to be admitted to the Official List and to the London Stock Exchange for the Placing Shares to be admitted to trading on the Main Market of the London Stock Exchange. It is expected that Admission will become effective at 8:00 a.m. on 30 March 2021 and that dealings in the Placing Shares will commence at that time.

Total Voting Rights

On Admission, the Company will have 591,609,368 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares and voting rights will be 591,609,368 and this figure may be used by Shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular dated 10 March 2021, a copy of which is available to view on the Company's website (www.nuformix.com).

 

Enquiries:

Nuformix plc

Dr Anne Brindley, CEO

Fleur Wood, Investor Relations

 

Allenby Capital Limited

Tim Sohal / Matt Butlin (Sales and Corporate Broking)

Nick Athanas / George Payne (Corporate Finance)

+44 (0)1223 627222

 

 

 

+44 (0)203 328 5656

 

 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

 

For more information, please visit www.nuformix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMUKURRANUOUAR

a d v e r t i s e m e n t